ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Transdermal vs. Injections of Testosterone
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 17703" data-attributes="member: 3"><p>Am J Physiol Endocrinol Metab. 2015 Apr 21:ajpendo.00111.2015. doi: 10.1152/ajpendo.00111.2015. [Epub ahead of print]</p><p></p><p><strong>Injection of Testosterone May be Safer and More effective than Transdermal Administration for combating Loss of Muscle and Bone in Older Men.</strong></p><p><strong></strong></p><p>Borst SE1, Yarrow JF2.</p><p></p><p></p><p></p><p>Abstract</p><p>The value of testosterone replacement therapy (TRT) for older men is currently a topic of intense debate. While US testosterone prescriptions have tripled in the last decade (7), debate continues over the risks and benefits of TRT. TRT is currently prescribed for older men with either low serum testosterone (T) or low T plus accompanying symptoms of hypogonadism. Serum T &#8804; 300 ng/dL is considered to be low and T &#8804; 250 is frank hypogonadism. Treatment for men who have low T without accompanying symptoms remains somewhat controversial. TRT produces benefits including increased muscle mass and strength, decreased fat mass, increased and bone mineral density. TRT also produces known risks including development of polycythemia, decrease in HDL, breast tenderness and enlargement, prostate enlargement, and increases in serum PSA and prostate-related events. Importantly, TRT does not increase the risk of prostate cancer. Several recent reports have also indicated that TRT may produce cardiovascular (CV) risks, while others report no risk or even benefit. To address the potential CV risks of TRT, we have recently reported via meta-analysis that oral TRT increases CV risk and suggested that the CV risk profile for i.m. TRT may be better than that for oral or transdermal TRT. Herein, we review the literature which indicates that i.m. TRT produces greater musculoskeletal and may be safer that either oral or transdermal preparations. We also review the literature discussing the use of 5&#945;-reductase inhibitors as a promising means of improving the safety profile of TRT.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 17703, member: 3"] Am J Physiol Endocrinol Metab. 2015 Apr 21:ajpendo.00111.2015. doi: 10.1152/ajpendo.00111.2015. [Epub ahead of print] [B]Injection of Testosterone May be Safer and More effective than Transdermal Administration for combating Loss of Muscle and Bone in Older Men. [/B] Borst SE1, Yarrow JF2. Abstract The value of testosterone replacement therapy (TRT) for older men is currently a topic of intense debate. While US testosterone prescriptions have tripled in the last decade (7), debate continues over the risks and benefits of TRT. TRT is currently prescribed for older men with either low serum testosterone (T) or low T plus accompanying symptoms of hypogonadism. Serum T ≤ 300 ng/dL is considered to be low and T ≤ 250 is frank hypogonadism. Treatment for men who have low T without accompanying symptoms remains somewhat controversial. TRT produces benefits including increased muscle mass and strength, decreased fat mass, increased and bone mineral density. TRT also produces known risks including development of polycythemia, decrease in HDL, breast tenderness and enlargement, prostate enlargement, and increases in serum PSA and prostate-related events. Importantly, TRT does not increase the risk of prostate cancer. Several recent reports have also indicated that TRT may produce cardiovascular (CV) risks, while others report no risk or even benefit. To address the potential CV risks of TRT, we have recently reported via meta-analysis that oral TRT increases CV risk and suggested that the CV risk profile for i.m. TRT may be better than that for oral or transdermal TRT. Herein, we review the literature which indicates that i.m. TRT produces greater musculoskeletal and may be safer that either oral or transdermal preparations. We also review the literature discussing the use of 5α-reductase inhibitors as a promising means of improving the safety profile of TRT. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Transdermal vs. Injections of Testosterone
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top